Member Info for bignose58

This certainly could be a driver for a rerate.......As usual compliments of POM

https://www.eurekalert.org/pub_releases/2021-02/dll-pca021021.php

FSB

I'm sure everyone feels they should have sold out on the EU approval (and bought back in at 0.065...lol), however. No one did because RPG's presentations indicated reasonable sales. Unfortunately they (RPG and Recordati) didn't do any homework regarding market research and just based it all on ED figures without the stigma. Hindsight is an amazing thing.....unfortunately we are all paying the price with the dilution since then....what is it about 35% (excluding Jamie's shares which I am sure he will take next year as loan repayment).

Anyroadup, seems they have learnt their lesson with respect to the USA and some detailed market Research is underway. Either this year or next could be quite transformational with the US license agreement and China....woof woof......lol

So based on the 10k share lot size.

For every 10K shares owned =====> 0.255 x 10,000 = 2550HKD ====> divide by 10.8 = 236 squid.

So for for every 10k shares = 236 squid.

FSB

(Share price x number of shares you own)/Exchange rate (currently 10.8 HKD to GBP)

A nice finish today up nearly 20% on a 2.85 buy/sell ratio.

Sp high of 0.265 (24.4%), so not too big a drop back.

Will it continue tomorrow or will there be a sell off from profit taking or will it continue if there is indeed news today ?

Hi DWG

You could indeed be right, It all depends on how quickly they can recruit 150 sufferers, although I still don't see the need for the trial myself...No logical reason given the HK/Macau and Taiwan launches.

Obviously something is afoot....an announcement maybe later today ? Has the phase II data been submitted ?

Anyway, nice to see and that I'm currently back in profit.....lol

Interesting to see how it closes.

The.Italian

No lost sleep, just tht I may have missed something somewhere along the line.

Not your system as I too have posted and nothing has shown. Post however are registered since if I were to click on my name, it would list all posts including the missing one. Eventually they appear (just as your has) sometime later.

Morning The.Italian

Maybe you can clarify your recent FUM posting which has the above thread title you started. Did you accidentally get confused with DLI and ED since I wasn’t aware DLI were looking at any ED development or have I missed something.....scratching head.
;-)

And as you state probably some MM manipulation since there are probably not many free shares available.

Heimdal

No problem, but pls DYOR as to possibilities, although it does look promising.

More likely profit taking as it has increased quite a lot recently.

Their timing regarding Nuvec, a novel delivery system for cancer treatments and vaccines, couldn't have come at a better time.......if it works as stated, it could skyrocket the company........ a long time into the future.

I recall that Dr Mike worked with someone from the company at Pfizer. His opinion was that what they had wouldn't be any good (reformulation of sildenafil) since one could just crush a Viagra tablet, rub it under the hood and you would be good to go, however.....Seems what they had didn't work anyhoo........ That said, it probably was a godsend since they moved onto something totally different which could be a lot more lucrative and they don't have to reformulate anything (isn't reformulation a sort of muted legal plagiarism anyway......lol)

20th Nov 2018....

N4 Pharma Plc (AIM: N4P), the specialist pharmaceutical company, today announces that, following the receipt of the final report of the clinical trial for its reformulation of sildenafil, the Board has undertaken a strategic review of the business. The findings and implications are as follows:

Results of the full clinical data: As announced on 9 July 2018, the Company received the preliminary results of the pharmacokinetic ("PK") data from its clinical trial for the reformulation of sildenafil, which showed that the formulation had not met the key target endpoints of the trial.

I see N4p took off yesterday on the back of a patent approval. if what I have read is correct, it could do very very well. Doubled in the last 6 months and up 5 times in the last 12 and still only a market cap of 24mill.

I think they were originally developing an ED application which, for some reason, they kicked it into touch. What they have now is a totally different kettle of fish. Anyway.....

Worth watching just for entertainment value..lol......... As usual, DYOR

There are no excuses now ... :-)

https://www.fiercebiotech.com/cro/fda-urges-clinical-researchers-to-go-virtual-response-to-covid-19-pandemic

https://www.reuters.com/article/us-health-coronavirus-fda-idUSKBN2152IP

A fair morning today with buys outweighing sells which hasn’t occurred for a while......apart from yesterday, I should have added :-)

Yes, it was a strong finish which, as you say, could bode well., although. even though we are up 10% over the last couple of days, that can, as we know, be eroded very easily. Hopefully all the recent announcements with expectations of others to come will help sustain the motivation and positivity of "this could now be a worthwhile investment". :-)

A fair morning today with buys outweighing sells which hasn’t occured for a while (even with small positive finishes). Seems some may not have read the announcement till after close yesterday, anyways. It’s been a while since we were this high at close.

Closed for CNY till Tuesday next week (year of the ox), so expect plenty of bull next week/year .... lol.

Gong Xi Fa Cai.

In pharma.....lol

The story of RPGs life......

In reflection. We had a years delay on the China submission due to missing documentation. Just think, we could have been heading to a point of approval about now instead of having to wait yet another year.

And past errors..... :-)